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The host defense system of the skin is composed of 1) a barrier, 2) innate immunity, 
and 3) acquired immunity. Inflammatory skin diseases can be classified into one of 
the disorders of these layers of the defense system, unless there is an ordinary 
response to specific infectious agents or internal/external injury. Any inflammatory 
skin disease partly simulates the response to real infections or dangers. Disorders of 
acquired immunity can be classified into 1) immunodeficiency, 2) 
immunohyperactivity (allergy), and 3) qualitative disorder (autoimmunity). Disorders 
of innate immunity can be classified into 1) innate immunodeficiency, 2) innate 
immunohyperactivity (general or local autoinflammation), and 3) qualitative disorder 
(general or local innate autoimmunity). The barrier of the skin is composed of 1) the 
physical barrier and 2) the chemical barrier. Several diseases, such as atopic 
dermatitis, are attributed to the disorder of these components of the barrier. Here, we 
propose an algorithm to classify the pathology of inflammatory skin diseases by 
means of what disorder in the specific layer of the host defense system is truly 
responsible. 
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1. Layers of the host defense system 
 
The host defense system of the skin is mainly composed of the following three layers: 
1) barrier of the skin, 2) innate immunity, and 3) acquired immunity [1]. In general, 
these layers are aligned in this order chronologically, functionally, and 
phylogenetically. A disorder in a specific layer can arise from defects in the superior 
layer. Each layer has unique roles to protect the body against specific infectious 
agents and external/internal dangers. Inflammation is defined as a series of protective 
and regenerative responses of the body. Therefore, inflammatory skin diseases are 
originally a result of these protective and regenerative responses of the skin against 
infections and dangers. If primarily causative infections and dangers are ruled out, the 
dermatitis is due to hereditary or acquired disorder in a specific layer of the host 
defense system. 
 
Descriptive dermatology of the morphological phenomena of skin has been developed 
for more than two thousand years. Despite recent and ongoing progress in 
immunology, innate immunity, and the skin barrier, inflammatory skin diseases have 
not yet been fully classified in terms of the defects in each layer of the host defense 
system.  
 
In this review, we propose a new algorithm to understand the pathology of 
inflammatory skin diseases in terms of the specific roles of each three layer in host 
defense system of the skin (Box). We describe the disorder of these layers in reverse 
order from acquired immunity to barrier, for the better understanding (see Chapter 5). 
Physiological disorders of the body machine can be divided into quantitative disorders 
and qualitative disorders. We classified the disorders of this dichotomy, except for the 
disorder of barrier, whose understanding is insufficient for this classification (Table 
1). This classification proposed here would be effective to clarify the current 
problems and the directions of research in this field.  









A number of hereditary diseases have been identified as a genetic lack of the specific 
molecules that are essential in acquired immunity. Many of them are associated with a 
variety of cutaneous infections and inflammation. For example, X-linked 
agammaglobulinemia (XLA) develops furunculosis, impetigo, and atopic-like 
eczematous eruptions. X-linked lymphoproliferative (XLP) disease is highly 
accompanied by infectious mononucleosis due to Epstein-Barr virus (EBV) infection. 
Chronic mucocutaneous candidiasis (CMCC) is composed of heterogeneous diseases, 
some of which have molecular defects in the acquired immunity, such as defects in 
the autoimmune regulator (AIRE) gene (See Chapter 2.3.1) [2]. Acquired 
immunodeficiency syndrome (AIDS) patients are highly susceptible to fungal and 
herpes virus infection, such as human herpes virus 8 (HHV8), and patients develop 




Another face of acquired immunity is an antitoxin, which neutralizes toxic agents 
such as venoms and poisons from insects, worms, and plants in nature [3]. However, 
hyperactivity of acquired immunity to a specific antigen results in allergic diseases. 
An allergy can be divided into two groups by the course of sensitization. One is an 
allergy with irritative and destructive sensitization, such as allergies to wasps and 
poison ivy. Another is an allergy without remarkable damages on the body at the 
sensitization phase, such as food allergies, and allergies to the cosmetic and industrial 
materials. The former allergy is originally beneficial and protective for species, 
whereas the latter is not. 
 
As for the skin, allergic contact dermatitis is thought to have originated as a beneficial 
response in the skin, to eliminate toxic molecules and harmful insects and worms by 
oozing, acanthosis, hyperkeratosis, and exfoliation in the epidermis, accompanied by 




well as a new exposure condition of the existing materials for an ethnic, such as 
manufactured metals and peanut oil in industrial materials, can accidentally elicit 
acquired immunity in limited responders. Most people commonly inherit the former 
allergy, which is usually associated with irritant dermatitis by toxic allergens at the 
sensitization phase [3]. However, the latter allergy has not yet been phylogenetically 
inherited or eliminated for thousands of years, regardless of whether it is beneficial or 
not. Thus, the latter allergies to cosmetic materials, industrial products, and 
unspecified materials suffer limited people only since specific events in the history of 




Autoimmunity is a qualitative disorder mainly due to trouble within the organization 
of immune tolerance, which is essential for acquired immunity. Both central tolerance 
in the thymus and peripheral tolerance in extrathymic tissues are indispensable to 
avoid severe systemic autoimmune diseases. Here, two basic questions are raised. 1) 
Is a breakdown of the tolerance a primary disorder of acquired immunity or a 
secondary disorder attributed to the preceding layers of the host defense system in 
‘classical’ systemic autoimmune diseases? 2) Are there any antigen-specific 
breakdowns of tolerance or anergy involved in the pathogenesis of organ-specific 
autoimmune diseases? 
 
2.3.1. Systemic autoimmunity 
 
Autoimmune diseases are classically divided into systemic and organ-specific 
autoimmune diseases. Mice with lpr or gld mutation develop systemic autoimmune 
disease [4]. They possess loss-of-function mutation in Fas or FasL, respectively, 
which are necessary for the negative selection of autoreactive T and B-lymphocytes in 
thymus and extrathymic tissues. In humans, Fas mutation also develops autoimmune 
lymphoproliferative syndrome (ALPS) that presents similar clinical features as lpr 
mice. Defect in AIRE develops multiorgan disease in mice and humans as 
autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) [5]. 




called immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) 
syndrome [6].  
 
 However, despite a number of regulatory molecules of acquired immunity, there is 
limited evidence showing that they are definitely involved in the pathogenesis of 
systemic autoimmune diseases. It is obscure whether most systemic autoimmune 
diseases are due to primary disorder of acquired immunity or secondary disorder 
caused by the primary disorder in the innate immune system (see chapter 3).  
 
2.3.2. Organ-specific autoimmunity 
 
There are quite a few hypotheses to explain the breakdown of antigen-specific 
tolerance to an autoantigen. Infections precede some organ-specific autoimmune 
diseases, and cross-reactivity and bystander activation of autoreactive T-lymphocytes 
are implicated in their pathogenicity. Viral infections appeared to precede the onset of 
type-I diabetes mellitus. In skin diseases, fogo selvagem, an endemic pemphigus 
folliaceus, anti-desmoglein 1 autoantibodies cross-react with sand fly salivary antigen 
[7]. However, most cases of autoimmune skin diseases lack apparent evidence of 
preceding infection or inflammation. 
 
Organ-specific autoimmune diseases may not be due to a disorder of acquired 
immunity, but may instead be due to acquired changes in the antigenicity of self-
antigens. For example: 1) Autoantibody in linear IgA bullous dermatosis (LAD) 
recognizes neoepitopes generated by ectodomain shedding of 180-kD bullous 
pemphigoid antigen (BP180)/type XVII collagen [8, 9]. 2) Laminin 332 from cancer 
cells possess unique laminin globular (LG) 4 and 5 domains, suggesting preferential 
association of anti-laminin 332 mucous membrane pemphigoid with malignancy [10]. 
3) Laminin γ1 is a ubiquitous, highly glycosylated protein. Autoantibodies from anti-
laminin γ1 pemphigoid do not react with blood vessel-derived, but do react with skin-
derived laminin γ1, suggesting that the autoantibody recognizes unique glycosylation 
patterns [11]. Thus, post-translational modification of autoantigens may lead the 
normal response of acquired immunity to the newly arisen epitopes in individuals 







3. Disorder of innate immunity in skin diseases 
 
Despite the large number of TLRs, RIG-I-like receptors (RLRs), and the other pattern 
recognition receptors (PRRs), only a few transcription factors drive the innate 
immune response of an organism (Figure 1). In other words, the immune system has 
evolutionally developed to interpret the activation patterns of a couple of essential 
transcription factors to elicit the most suitable type of immune response, and protected 
an organism against specific infectious agents [12-14]. Thus, one can imagine that the 
defective homeostatic balance of the activation state of these transcription factors is 
crucial in the development of inflammatory skin diseases simulating the real innate 
immune responses to infectious agents and dangers (Figure 2).  
 
3.1. Innate immunodeficiency 
 
Primary immunodeficiencies are partly defined as genetic deficiencies in the innate 
immune system [15, 16]. Innate immune receptors, such as TLRs, recognize 
conserved pathogen-associated molecules that are shared by different microorganisms, 
and subsequent engagement can trigger the production of inflammatory cytokines and 
chemokines through the nuclear factor-κB (NF-κB)-dependent and interferon (IFN)-
regulatory factor (IRF)-dependent signaling pathways (Figure 1) [15]. Complete 
defects in each of two main TLR-dependent pathways have been reported so far [16]. 
The first is a defect in myeloid differentiation primary response 88 (MyD88) or 
interleukin (IL)-1 receptor-associated kinase 4 (IRAK4), which lacks NF-κB-
dependent expression of pro-inflammatory cytokine, and leads to greater 
susceptibility to pyogenic bacteria in early infancy. The second is a defect in the 
TLR3-TRIF-TRAF3 pathway, which lacks expression of type 1 IFNs, and results in 
greater susceptibility to herpesviruses [16]. 
 
Dominant negative mutations in STAT3, another transcription factor regulating the 
expression of a number of cytokines and growth factors, causes unique primary 




like skin lesions, cold abscesses, and CMCC characterize the skin manifestations of 
this syndrome although precise mechanisms underlying this syndrome remain unclear. 
 
Defects in myeloid cells or components of the complements in inflammatory skin 
diseases are described elsewhere [18, 19]. 
 
3.2. Innate immunohyperactivity 
 
3.2.1. Systemic innate immunohyperactivity: Autoinflammatory diseases 
 
“Excessive” innate immune responses characterize systemic autoinflammatory 
diseases. A number of autoinflammatory syndromes are caused by single gene 
mutations that are crucial in the regulation of interleukin (IL)-1 [20-22]. For example, 
a gain-of-function mutation in NLRP3, a component of inflammasomes, causes 
cryopyrin-associated periodic syndrome (CAPS). Deficiency of IL-1 receptor 
antagonist (DIRA), TNF receptor-associated periodic syndrome (TRAPS), and IL-10 
receptor deficiency are included in monogenic, systemic autoinflammatory diseases. 
Anti-IL-1 therapy is the standard of care in treating CAPS and other 
autoinflammatory diseases [23]. 
 
Some polygenic, systemic autoinflammatory diseases partly share their clinical states, 
pathogenesis, and responsible genes with monogenic autoinflammatory diseases. [24]. 
Behçet’s disease has been classified as an autoinflammatory disorder [25, 26]. Two 
large genome-wide association studies (GWASs) reported the association between 
Behçet’s disease and the single nucleotide polymorphism (SNP) of IL-10, IL-23R/ IL-
12RB2, TRAF5, and TRAF3IP2 genes [27-29]. Pyoderma gangrenosum, 
characterized by sterile neutrophilic infiltration of the skin and other organs, is one of 
the clinical manifestations of a monogenic autoinflammatory disease, pyogenic 
arthritis, pyoderma gangrenosum, and cystic acne (PAPA) syndrome [22], in which 
CD2BP1 mutation results in the activation of the NLRP3 inflammasome [24]. A 
clinical study demonstrated that infliximab, a monoclonal antibody against tumor 





3.2.2. Organ-specific innate immunohyperactivity: Acne, pyoderma chronica, and 
rosacea 
 
In some diseases, hyperactivity of the innate immune response is highly specific to 
skin appendages. Therefore, it is convenient to understand that unique and distinctive 
pathomechanisms are involved in the folliculosebaceous units-specific innate 
hyperactivity. Folliculosebaceous units are known to be immune privileged sites, 
which prevent sensitization and elicitation of an antigen-specific, acquired immune 
response. On the other hand, it would also be theoretically appropriate to say that the 
state of the defect in the ‘innate’ immune privilege in folliculosebaceous units elicits 
hyperactivity of the innate immunity in these organs. 
 
The pathogenesis of acne is multifaceted, and it was originally thought that 
inflammation follows comedo formation. However, there is evidence that dermal 
inflammation may actually precede comedo formation [31]. Human follicular 
keratinocytes demonstrate hyperproliferation and microcomedone formation when IL-
1α is added [32]. IL-1 receptor antagonists inhibit microcomedone formation [33]. P. 
acnes has been shown to stimulate the release of proinflammatory cytokines, such as 
IL-1α, IL-8, IL-12, and TNF-α by binding to TLR2 on monocytes and 
polymorphonuclear cells surrounding the sebaceous follicle [34]. 
 
As well as acne, chronic pyodermas, such as dermatitis papillaris capillitii, 
hidradenitis suppurativa, and pyodermia chronica glutealis, develop in several 
monogenic autoinflammatory disorders. Despite bacterial colonization and infection, 
they are not always a primary reason for these diseases. Defective Notch-induced 
organogenesis can also be associated with cyst formation in these diseases [35]. 
 
In rosacea, lesional keratinocytes show TLR2 upregulation and increased receptor 
sensitivity leading to a higher expression and activity of serine proteases of the 
kallikrein family. [36]. Kallikrein is involved in the processing of cathelicidin 
antimicrobial peptides (CAMPs) and other smaller fragments, which are involved in 
the pathogenesis of rosacea (see chapter 4. 2. 2). Although the trigger for TLR2 in 
rosacea remains unspecified,  chitins and Bacillus oleronius from Demodex 




hyperactivation of a specific TLR signaling pathway in folliculosebaceous units can 
be a primary disorder and precede the dysfunction of CAMPs in rosacea.  
 
 
3.3. Innate autoimmunity 
 
While autoinflammatory diseases are defined as a quantitative disorder of the innate 
immune response, many other diseases have been implicated as involving defects in 
the innate immune system: 1) they are not explained simply by an excessive 
activation of innate immunity and 2) activation of autoreactive lymphocytes is 
inevitable for pathogenesis. Here, we name this group “innate autoimmunity” as a 
qualitative disorder of the innate immune system. 
 
3.3.1. Systemic innate autoimmunity: “Classical” systemic autoimmune diseases 
 
Recent work highlighted the important role of innate immunity and IFN-α signaling in 
the pathogenesis of both systemic lupus erythematosus (SLE) and systemic sclerosis 
[12, 13]. The activation of plasmacytoid dendritic cells (pDCs) by circulating immune 
complexes following release of neutrophil extracellular traps (NETs) is an early 
trigger of autoimmunity in patients with SLE, by directing the chronic IFN-α 
production [37, 38]. NETs immobilize and kill invading microbes through a unique 
form of neutrophil cell death, NETosis. Antimicrobial peptide LL-37 antibody is 
expressed at high levels in SLE. NET-associated LL-37-DNA immune complex, 
together with anti-LL-37 or anti-DNA autoantibodies, appears to stimulate the 
production of IFN-α by pDCs, and may also prompt autoreactive B-cell activation 
[39]. Several microarray analyses have revealed a genomic “signature” of upregulated 
IFN-α-inducible genes from peripheral blood mononuclear cells of SLE and systemic 
sclerosis patients [40, 41]. IFN-α is induced by pDCs in systemic sclerosis 
presumably through RNA binding with TLR7 [42].  
 
Thus, the disorder of the innate immune response can promote systemic 
autoimmunity and precede the expansion of autoreactive lymphocytes and tissue 




shown to inhibit TLR signaling, and it may be through this mechanism of action that 
antimalarials display efficacy in lupus [43]. 
 
3.3.2. Organ-specific innate autoimmunity: Psoriasis 
 
Next, one would easily come up with the idea of organ-specific innate autoimmunity 
among inflammatory skin disorders. The early events and players in the proposed 
pathogenesis of SLE described above are very similar to that which were recently 
proposed in the pathogenesis of psoriasis [44], although the functional character of the 
T effector lymphocytes and the resulting histological and clinical features are quite 
different. In psoriasis, it is suggested that the breakdown of tolerance to self-nucleic 
acids occurs when self-DNA and -RNA aggregate with the LL-37 [44]. By inducing 
pDC activation and type I IFN production, LL-37-self-DNA complexes initiate a 
pathogenic cross talk between stressed epidermal cells and recruited pDCs. pDC-
derived IFN-α promotes the maturation and activation of bystander myeloid DCs, 
which are key to sustaining and amplifying T cell responses in skin inflammation. 
 
Gain-of-function mutations in caspase recruitment domain  (CARD) 14, potentially an 
upstream regulator of IκB kinase (IKK) β, have been identified in the familial type of 
psoriasis and pityriasis rubra pilaris (PRP) [45, 46]. On the contrary, the mice lacking 
IKKβ in the epidermis develop psoriasiform dermatitis, and a high amount of IL-24 
produced from the keratinocytes precedes the infiltration of neutrophils and 
lymphocytes and disease development [47]. IKKβ is a master kinase at the bottleneck 
of the NF-κB, IRF3, IRF7 and MAPK signaling pathways downstream of PRRs. 
However, the transcriptional factors that are directly involved in the pathogenesis of 
the epidermis-specific IKKβ knockout, and the skin lesions in human psoriasis and 
PRP, have not been completely specified.  
 
 
4. Disorders of the barrier in skin diseases 
 
In this article, as described above, we consider a barrier to be fundamental structure 
and system that is not inducible, but is permanent and preventive against external 




elements: 1) A physical barrier, which is a visible structure covering the outside of the 
body to protect an organism against any external dangers. 2) A chemical barrier, 
which is invisible and composed of the biologically active molecules, is constitutively 
produced at the surface of the body to attack and neutralize the potential invaders. In 
other words, a physical barrier is a shield while a chemical barrier is a landmine at the 
interface of the external environment and the surface of an organism. Disorder in the 
physical barrier is usually accompanied by disorder of the chemical barrier. Although 
the disorder of a barrier cannot yet be clearly determined quantitatively or 
qualitatively, several diseases, such as atopic dermatitis, can be attributed to disorder 
of the specific components of the barrier. 
 
4.1. Defects in the physical barrier: Atopic dermatitis 
 
Atopic dermatitis is not a monogenic disorder. However, it has been well accepted 
that defects in the physical barrier are involved in the pathogenesis of, and continuous 
inflammation in, atopic dermatitis [48]. Filaggrin governs multiple components of the 
physical barrier in the skin. Loss-of-function mutations in the gene encoding filaggrin 
cause ichthyosis vulgaris. Filaggrin gene mutations are detected in 20 to 50% of 
patients with atopic dermatitis in Europe and Japan [49, 50] and are also associated 
with bronchial asthma [51].  
 
There is evidence that primary defects in the other components of the physical barrier, 
such as corneodesmosin [52] or desmoglein 1 [53], causes atopic dermatitis-like 
dermatitis with hyper IgE levels and eosinophilia. However, the common defect in the 
physical and chemical barrier in these diseases and atopic dermatitis remains 
undetermined. The lack of claudin-1 gene coding a tight junction protein in humans 
leads to ichthyosis not eczema [54] despite diminished expression of claudin-1 and 
claudin-23, and association of SNPs in claudin-1, in patients with atopic dermatitis 
[55]. 
 
A number of recent investigations suggest that a vicious cycle of the defects in the 
physical barrier and eczema is involved in the persistence of the atopic dermatitis [48]. 




diminish the expression of the molecular components of the physical barrier, and the 
scratching behavior damages the physical barrier and accelerates skin inflammation. 
 
Then why do not all patients with ichthyosis vulgaris develop atopic dermatitis? It is a 
natural idea that atopic dermatitis requires second and third cues for anything but 
barrier. In terms of the barrier, however, we propose three possibilities to explain this 
paradox: 1) Disorder in the normal flora of the skin may be a principal defect in 
atopic dermatitis. The skin topography of microbes elegantly proposes the interaction 
of the skin microbiome and the frequently affected sites in atopic dermatitis [56]. The 
bacterial flora on the skin can shape and affect the development of the acquired 
immune system, and the defects in the physical barrier may reduce the threshold of 
immune modulation. 2) Defects in the physical barrier are heterogeneous and only an 
unspecified defect is responsible for the development of atopic dermatitis. 3) Atopic 
dermatitis may not be a disease of the defective physical barrier, but rather a disease 
of the defective chemical barrier. 
 
Certainly, only a defect of the barrier simulating damages on the surface of the skin 
by real invaders, such as scabies, hookworms, dermatophytes, and staphylococci, may 
provide molecular cues and elicit eczematous inflammation and an itchy sensation, 
which is reasonable for protecting the body from these agents. This process may 
involve defects in the chemical barrier, as discussed in the following section. 
 
4.2. Defects in the chemical barrier 
 
The interface of the external circumstance and the surface of the body is also 
protected by chemical materials, such as acids [57], reactive oxygen species (ROS) 
[58], lipid mediators like prostanoids [59], lysozymes and antimicrobial peptides 
(AMPs) [60, 61], and protease inhibitors [62], which are abundantly produced in the 
uppermost layer of the skin. The chemical barrier is the most basic and 
phylogenetically ancient system for an organism to protect oneself. Only effective 
systems have been phylogenetically selected and inherited among host-infection 
interaction, and innate immunity and adoptive immunity have effectively utilized this 
preceding mechanism for more selective protection in an elaborate manner. Therefore, 




specific dangers and infectious agents, and its defects can result in unique forms of 
skin inflammation.  
 
4.2.1. Proteases and protease inhibitors 
 
Endogenous proteases are important in 1) the keratinocyte differentiation and the 
desquamation process of the cornified layer [62], and 2) processing and regulation of 
the defense molecules in the epidermis [63].  On the other hand, there are numerous 
endogenous protease inhibitors, such as cystatins and lymphoepithelial Kazal-type-
related inhibitor (LEKTI). They regulate the proteolytic activity of endogenous 
proteases in the epidermis [63]. They may also control the proteolytic activity of the 
exogenous proteases from microorganisms and hamper their adhesion and 
transmigration. For example, proteolytic cleavage of cathelicidin produces LL-37 and 
another bioactive fragment that has cystatin-like activity [64]. Thus, the delicate 
balance of proteases and protease inhibitors contributes to the physical and chemical 
barrier function of the skin. 
 
Cysteine proteases are known to be a strong Th2 adjuvant [65], and are a major 
antigen from parasitic helminthes, the infection of which elicits a robust Th2 response 
[66]. Cysteine proteases are contained in a number of antigens and allergens, such as 
house dust mite antigens, staphylococcal antigens, and sweat, all of which are known 
to be complicating factors in atopic dermatitis. Indeed, papain, a cysteine protease 
from papaya, causes occupational asthma [67]. A cysteine protease, papain or Der p1, 
directly induces thymic stromal lymphopoietin (TSLP) and IL-33 secretion from lung 
epithelial and stromal cells [68-70], activation of dermal basophils [71], dendritic 
cells [72, 73], and innate lymphoid cells (ILCs) [68], and subsequent Th2-responses 
in animal experimental models. Cysteine proteases hold central roles in the regulation 
of cell apoptosis [74]. Various evidence suggests that cysteine proteases are involved 
in inflammasome activation [75] and processing of the IL-1 family cytokines [21, 76] 
and TLRs [77]. However, the precise mechanism of how their protease activity 
contributes to activating target cells for the induction of the Th2-type immune 
response remains unknown [65, 78]. Th2 induces excessive discharge from the gut 
and respiratory tract, as well as itchy and oozy dermatitis. These responses are quite 




tempted to speculate that the disorder of the homeostasis in cysteine protease 
activities in the skin induces the Th2-type immune response and subsequent 
eczematous skin lesions. 
 
The molecular mechanism by which serine proteases directly induce the Th2-type 
immune response has been clarified through extensive efforts [63]. Activation of a 
receptor for serine proteases, protease-activated receptor 2 (PAR2), is involved in the 
Th2 immune induction through TSLP expression. Loss-of-function mutations in the 
SPINK5 gene, encoding serene protease inhibitor LEKTI, result in Netherton 
syndrome, characterized by ichthyosis and persistent atopic eczema-like skin lesions 
in humans, and similar skin manifestations in mice. 
 
4.2.2. Antimicrobial peptides 
 
There are numerous AMPs identified in keratinocytes, including human β-defensins 
(HBD)-1, -2 and -3, cathelicidin (LL-37) and psoriasin (S100A7) [61]. In addition to 
their antimicrobial effects, they have roles in migration of granulocytes, dendritic 
cells, and T-lymphocytes and the activation of the innate and acquired immune 
responses.  
 
The expression of AMPs is downregulated in atopic dermatitis, probably due to the 
effect of the Th2 cytokines IL-4 and IL-13 [61]. High levels of aberrantly processed 
forms of cathelicidin peptides contribute to the increased inflammation in the rosacea 
skin [61]. In psoriasis, as mentioned in the preceding section, cathelicidin self-DNA 
complexes promote activation of TLR9 on pDCs in the dermis, resulting in enhanced 
cutaneous inflammation that contributes to its pathogenesis [61]. 
 
Thus, the levels of AMPs expression are related to the specific states of cutaneous 
inflammation. However, expressions of a considerable part of AMPs can be modified 
by the innate and acquired immune response [61]. Therefore, disorder of the AMPs in 
several inflammatory skin diseases might not be a primary, but a part of the secondary 
responses while AMPs can be involved in the persistence of the diseases. 
 





ROS are constantly produced in the skin, because skin is exposed to oxygen from 
outside and the oxygen is activated by light [58]. ROS have potent inflammation-
inducing and immunomodulatory properties. ROS provide an important host defense 
mechanism against microbial invasion, and therefore, are probably involved in the 
pathogenesis of inflammatory skin diseases. Thus, ROS are a potential target of 
preventive and therapeutic drugs for inflammatory disorders as well as ischemic 
diseases and cancers. However, despite a great deal of descriptive information, the 
primary role and its defect in ROS regulation in cutaneous inflammation is poorly 
understood. 
 
It is well known that prostanoids are abundantly produced and that the prostanoid 
receptors are highly expressed in the skin [79]. The balance of prostanoid production 
and receptor expression has been revealed to be important for immune homeostasis in 
the skin. Recently, we reported that prostaglandin (PG) D2 is produced in the lesions 
of eosinophilic pustular folliculitis [80]. The metabolites of PGD2 induce sebocytes to 
produce eotaxin-3, which leads to infiltration of eosinophils. Thus, the disorder in 
PGD2 metabolism might be a primary defect in this disease and would explain the 
successful treatment of this disease by indomethacin, a cyclooxygenase inhibitor. 
 
Some defects of barrier components lead to selective susceptibility to specific 
pathogens, such as in epidermodysplasia verruciformis caused by mutation in the 
EVER1/TMC6 or EVER2/TMC8 genes [81]. Patients with epidermodysplasia 
verruciformis have persistent infection with human papilloma viruses although the 





The development of the host defense system is essential in the phylogeny of each 
organism. The components of the barrier, each of which has a unique role, are ready 
to protect an organism. The best-suited response of the innate and acquired immunity 
is elicited upon infections and dangers in order to survive them. On a crisis of the cell, 




1). However, the innate immune system amplifies these cues and the acquired 
immune system translates the signals most effectively (Figure 2). A defect at the 
specific site among these three layers of the host defense system of the skin can 
induce an inflammatory skin disease with unique manifestation, which partly 
simulates the actual protective response against infections and dangers (Table 1).  
 
One can classify the inflammatory diseases in the skin and other organs more 
comprehensively using an algorithm to understand the host defense system as three 
layers, and through consideration of the original purpose of the inflammation type and 
a primary defect among three protective layers in the disease (Figure 3). First, one 
should suppose infectious diseases in the perspective of inflammation induced by 
damages for the organs. Next one should consider primary defects in the acquired 
immunity, innate immunity and barrier in this order, which is opposite to the 
functional order, because of effectively differential diagnosis. Defective functions of 
the functionally preceding layer usually cause disorders in the following layers, 
although the acquired immune response affects innate immunity and barrier functions 
in some instances. If one cannot attribute the ongoing inflammation in the body to any 
primary defects in all the three layers, one could consider a proper response to 
artificial or iatrogenic disorders, such as drug adverse effects and graft-versus-host 
disease (GVHD), or endogenous disorders that simulate external dangers, such as 
gout. 
 
This new algorithm would also be effective to investigate the function and kinetics of 
the specific molecule and cell subsets in a disease, by focusing on the interaction of 
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Representative signaling pathways in epidermis involved in the defense system. TLR 
signaling pathways are mainly composed of MyD88-TRAF6-IKK-NF-κB pathway 
that induces transcription of NF-κB response genes, such as TNF, IL-6, IL-1β and 
TSLP, and TRIF-TRAF3-TBK1-IRF3/7 pathway that induces transcription of type-I 
IFNs and IL-33. MyD88-dependent transcription is also regulated by a part of MAPK 
pathway. ASK1, apoptosis signal-regulating kinase 1; Erk, extracellular-regulated 
kinase; HIF1, hypoxia-inducible factor-1; IFN, interferon; IL, interleukin; IRF, 
interferon regulatory factor; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated 
protein kinase; MEK, MAPK/ERK kinase; MKK, MAP kinase kinase; MyD88, 
myeloid differentiation primary response 88; NF-κB, nuclear factor kappa B; ROS, 
reactive oxygen species; RTK, receptor tyrosine kinase; TAK1, transforming growth 
factor beta-activated kinase 1; TBK1, Tank-binding kinase-1; TLR, Toll-like receptor; 
TNF, tumor necrosis factor; TRAF, TNF receptor-associated factor; TRIF, TIR-




Speculated relation among primary triggers from infectious agents and external 
dangers, transcription factors, type of immune responses, and resulting diseases in 
skin. TSLP is a NF-κB response gene and is involved in the induction of Th2 
response, typically resulting spongiotic dermatitis. Both expression of NF-κB 
response genes and Type-I IFNs are involved in interface/necrotic dermatitis. 
Psoriasiform dermatitis induced by Th17 response seems to be NF-κB independent 
since epidermis-specific depletion of IKKβ presents psoriasiform dermatitis with IL-
24 expression from epidermis although precise pathway has not been fully 
investigated. IFN, interferon; IL, interleukin; IRF, interferon regulatory factor; LPS, 
lipopolysaccharide; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor 






Algorithmic method to classify the inflammatory skin diseases by means of the 
defects in the three layers of the defense system in skin. AMPs, antimicrobial 
peptides; GVHD, graft-versus-host disease; ROS, reactive oxygen species. 
 
Table 1: 
Proposed classification of inflammatory skin diseases. AIDS, acquired 
immunodeficiency syndrome; CAPS, cryopyrin-associated periodic syndrome; 
CMCC, chronic mucocutaneous candidiasis; DAMPs, damage-associated molecular 
patterns; GVHD, graft-versus-host disease, IRAK4, IL-1 receptor-associated kinase 4; 
MyD88, myeloid differentiation primary response 88; PAMPs, pathogen-associated 
molecular patterns; PRP, pityriasis rubra pilaris; PRR, pattern-recognition receptor; 
ROS, reactive oxygen species; SCID, severe combined immunodeficiency; SLE, 
systemic lupus erythematosus.  
 
Box 
Core of the new classification of inflammatory skin diseases. 
 
Box	
Box: Core of the new classification of inflammatory skin diseases: 
•  Inflammation is defined as a series of protective and regenerative 
responses of the body. 
•  Host defense system of the skin is composed of a barrier, innate 
immunity and acquired immunity. 
•  Three layers of the protection drive the most suitable response 
against infectious agents and external dangers whereas the basic 
response at the transcriptional level in the cell is very limited. 
•  Disorder of the specific layer of the host defense system of the skin 
can induce an inflammatory skin disease, which partly simulates the 








































 LPS  Lectins?	
Epidermis	


































No or  
Not primary	
No or  
Not primary	






 – Bacterial, viral, fungal, etc 
Others: 
 – Trauma, irritants, ultraviolet, etc 
 – Foreign body reaction, etc 
Immunodeficiency 
Immunohyperactivity/Allergy 
 – Phylogenically protective or Not 
Autoimmunity 




– General or local 
Innate autoimmunity 
– General or local 
	
Defects in physical barrier 
Defects in chemical barrier 
 – Proteases and protease inhibitors 
 – AMPs 
 – Prostanoids, ROS, etc 
Proper reaction: 
 – GVHD, drug eruption, etc 
 – Gout, etc 
 – Organ-specific autoimmunity? 
Table 1
Category Acquired Immunity
Dangers Venoms and poisonsToxic haptens and allergens
Infectious agents
Ligands Protein antigens, etc











































MyD88 deficiency, IRAK4 deficiency, etc
Phagocyte dysfunction, etc
Chemical Barrier





Physical damages, foreign body, dead cells
Cellular and oxidative stress
PAMPs, DAMPs
PRRs
Bacteria, viruses, fungus and parasites
Any dangers
and infectious agents
None (parmanent, non-inducible)
